Omega-3 LCPUFA Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the nerve tissue in the eye which allows us to see. A recent study showed that giving omega-3 (n-3) fatty acids to these infants soon after birth made them less likely to need invasive treatments for eye disease. This research trial will give young infants born prematurely n-3 fish oil treatment and look at how this changes factors in the blood that promote disease. Detailed blood studies comparing infants with and without ROP will be performed and the infants will be followed over time to assess their eye development.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Collaborator: The Hartwell Foundation

Criteria

Inclusion Criteria:

• Infants born less than or equal to 30 weeks gestation or less than 1500 g at birth

Exclusion Criteria:

• Patients with liver disease as tested by LFTs.

• ≤ 500 grams birthweight